Mays Hospice Care, Inc 202 Nw J Street, Antlers, OK, 74523 | |
(580) 298-1154 |
News Archive
Less than every fourth child in Europe have enough fruit and vegetables included in their daily diet, a study by Swedish researchers at örebro University and Karolinska Institutet shows. The findings are a part of an EU-funded study and are presented in Public Health Nutrition today.
Many healthcare providers today try to avoid administering or prescribing opioid pain medications when possible because of the narcotics' addictive properties. But for some patients, opioid medications remain the most effective, most appropriate treatment for their subjective pain complaints.
VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.
NeoPharm, Inc., announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis.
› Verified 4 days ago
Name | Mays Hospice Care, Inc |
---|---|
Location | 202 Nw J Street, Antlers, Oklahoma |
Hospice ID | 371650 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
SSA county code | 630 |
News Archive
Less than every fourth child in Europe have enough fruit and vegetables included in their daily diet, a study by Swedish researchers at örebro University and Karolinska Institutet shows. The findings are a part of an EU-funded study and are presented in Public Health Nutrition today.
Many healthcare providers today try to avoid administering or prescribing opioid pain medications when possible because of the narcotics' addictive properties. But for some patients, opioid medications remain the most effective, most appropriate treatment for their subjective pain complaints.
VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.
NeoPharm, Inc., announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis.
› Verified 4 days ago
NPI Number | 1073545562 |
Organization Name | Mays Hospice Care, Inc |
Address | 202 Nw 'j' St. Antlers, Oklahoma, 74523 |
Phone Number | (580)298-1154 |
News Archive
Less than every fourth child in Europe have enough fruit and vegetables included in their daily diet, a study by Swedish researchers at örebro University and Karolinska Institutet shows. The findings are a part of an EU-funded study and are presented in Public Health Nutrition today.
Many healthcare providers today try to avoid administering or prescribing opioid pain medications when possible because of the narcotics' addictive properties. But for some patients, opioid medications remain the most effective, most appropriate treatment for their subjective pain complaints.
VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.
NeoPharm, Inc., announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis.
› Verified 4 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.3 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.3 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 94.1 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 100.0 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 98.5 | 97.3 |
Patients who got timely treatment for shortness of breath | 94.6 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 98.9 | 93.3 |
News Archive
Less than every fourth child in Europe have enough fruit and vegetables included in their daily diet, a study by Swedish researchers at örebro University and Karolinska Institutet shows. The findings are a part of an EU-funded study and are presented in Public Health Nutrition today.
Many healthcare providers today try to avoid administering or prescribing opioid pain medications when possible because of the narcotics' addictive properties. But for some patients, opioid medications remain the most effective, most appropriate treatment for their subjective pain complaints.
VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.
NeoPharm, Inc., announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis.
› Verified 4 days ago
Home Health Aides | 2 |
Counselors | 1 |
Homemakers | 2 |
Licensed Practical or Vocational Nurses | 1 |
Medical Social Workers | 1 |
Physicians | 1 |
Registered Nurses | 2 |
Total Employees | 10 |
---|
News Archive
Less than every fourth child in Europe have enough fruit and vegetables included in their daily diet, a study by Swedish researchers at örebro University and Karolinska Institutet shows. The findings are a part of an EU-funded study and are presented in Public Health Nutrition today.
Many healthcare providers today try to avoid administering or prescribing opioid pain medications when possible because of the narcotics' addictive properties. But for some patients, opioid medications remain the most effective, most appropriate treatment for their subjective pain complaints.
VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.
NeoPharm, Inc., announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis.
› Verified 4 days ago
Others | 2 |
Total Volunteers | 2 |
---|
News Archive
Less than every fourth child in Europe have enough fruit and vegetables included in their daily diet, a study by Swedish researchers at örebro University and Karolinska Institutet shows. The findings are a part of an EU-funded study and are presented in Public Health Nutrition today.
Many healthcare providers today try to avoid administering or prescribing opioid pain medications when possible because of the narcotics' addictive properties. But for some patients, opioid medications remain the most effective, most appropriate treatment for their subjective pain complaints.
VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.
NeoPharm, Inc., announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis.
› Verified 4 days ago
Mays Hospice Care, Inc Location: 202 Nw J Street, Antlers, Oklahoma, 74523 Phone: (580) 298-1154 |